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Background/aim: Allergic bronchopulmonary aspergillus (ABPA) is a lung disease caused by hypersensitivity from Aspergillus
fumigatus. Diagnostic criteria, staging systems and treatment methods for ABPA disease have been reported in studies evaluating
populations, the majority of which are adult patients. Our study aimed to discuss the use of ABPA diagnostic criteria in children, the
success of other alternative regimens to oral corticosteroids in the treatment of ABPA, and the changes that occur during treatment, in
the light of the literature.
Materials and methods: Between January 2017 and 2020, patients diagnosed with ABPA at the Dokuz Eylül University Child Allergy
and Immunology clinic were identified; demographic characteristics, clinical and laboratory findings, diagnostic scores and stages, and
treatment protocols were analyzed retrospectively.
Results: The mean age of patients diagnosed with ABPA was 14.33 ± 1.96. At the time of ABPA diagnosis, the median total IgE level
was 1033 IU/mL (1004–6129), and the median AF specific IgE was 10.64 (2.59–49.70) kU/L. Bronchiectasis was detected in HRCT of
5 cases. We detected significant improvement in spirometric analysis with omalizumab treatment in our patient with steroid-related
complications.
Conclusion: Today, although risk factors have been investigated for ABPA, it has not been revealed clearly. Both diagnostic criteria and
treatment regimens have been described in research studies, mostly adults. In pediatric patients; clarification of diagnosis and treatment
algorithms is necessary to prevent irreversible lung tissue damage and possible drug side effects.
Key words: Allergic bronchopulmonary aspergillosis, asthma, cystic fibrosis, child

1. Introduction
Allergic bronchopulmonary aspergillosis (ABPA) is a lung
disease caused by hypersensitivity to Aspergillus fumigatus
(AF), especially in asthma and cystic fibrosis patients [1,2].
Its prevalence varies between 2%–15% [3]. The diagnostic
criteria proposed by Rosenberg–Patterson in 1977 were
edited by Greenberger in 2007 and Agarwal et al. in 2016
[4–6]. In the case of fungal sensitivity accompanying
severe asthma patients, the detection of total IgE level
<1000 IU/mL suggests the diagnosis of severe asthma
with fungal sensitization (SAFS) [7]. For the treatment of
ABPA, corticosteroids, antifungal treatments, and antiIgE, monoclonal antibodies are used [1]. We aimed to
discuss ABPA diagnostic criteria, clinical and laboratory
findings, and the success of different treatment regimens
in the light of the literature on our children with ABPA
diagnosis.

2. Materials and methods
Between January 2017 and 2020, patients diagnosed with
ABPA at the Dokuz Eylül University Child Allergy and
Immunology clinic were identified. Patients’ demographic
characteristics, clinical and laboratory findings (total IgE,
Aspergillus fumigatus specific IgE, eosinophil count, SPT,
and spirometry values), treatment protocols were evaluated
retrospectively. Predisposing disease in patients was
determined. From these diseases; diagnosis of asthma was
made with the guidelines of Global Initiative for Asthma1,1
and the diagnosis of cystic fibrosis (CF) was made with
the American Council of Cystic Fibrosis 1998 consensus
report [8]. We used the diagnostic criteria of Agarwal R
et al. for the diagnosis of ABPA and the diagnostic criteria
of Denning DW et al. for the diagnosis of SAFS [6,7].
The diagnostic criteria of ABPA were; the presence of
predisposing disease (Asthma or cystic fibrosis, COPD,

Global Initiative for Asthma (2020). Global Strategy for Asthma Management and Prevention [online].Website https://ginasthma.org/gina-reports/
gina-2020-full-report_-final-_wms/ [accessed 03 April 2020].
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post-TB fibrocavitary disease) and with two obligatory
criteria that’s are AF specific IgE > 0.35 kU/L or positive
AF skin prick test (SPT) and total serum IgE > 1000
IU/mL; and with at least 2 of 3 the other criteria, the
presence of radiological findings compatible with ABPA
or serum AF IgG > 27 mg/L or total eosinophil count
>500 /µL We evaluated the situations that might be a risk
factor for the development of ABPA in patients [6]. If the
SPT ≥ 3 mm and allergen specific IgE ≥ 0.35 kU/L, the
presence of atopy was shown. Extracts of 16 common
allergens were used for the prick test (Allergopharma,
Merck KGaA, Darmstadt/Germany). Allergen extracts
included household mites (Dermatophagoides farinae,
Dermatophagoides pteronysinus), grass pollen mixtures
(Artemisia vulgaris, Grasses, Parietaria officinalis),
tree pollen mixtures (Alnus glutinosa, Betula alba,
Fagus silvatica, Populus alba, Olea europaea), moldmix (Alternaria alternata, Aspergillus fumigatus,

Cladosporium herbarum), and animal dander (Blatella
germanica, Canis familiaris, Felis domesticus). We
classified our patients with the diagnostic scoring and
staging criteria suggested by Agarwal et al. ABPA total
disease score was obtained by summing the radiological
and immunological scores (Table 1) [6].
The staging of ABPA is as follows:
Stage 0 (Asymptomatic); Asymptomatic cases who
have not previously been diagnosed with ABPA, meeting
ABPA diagnostic criteria.
Stage 1 (Acute), ABPA compliant with uncontrolled
asthma/symptoms.
Stage 2 (Response), 25% or more reduction in total
IgE at week 8 of treatment in addition to clinical and/or
radiological improvement.
Stage 3 (Exacerbation), increases clinically and
radiologically with worsening 50% or more compared to
the total IgE level determined in the treatment response/

Table 1. Recommended scoring system for the diagnosis of allergic bronchopulmonary aspergillosis (ABPA)
Immunological scoring

Value

Score

A. fumigatus-specific IgE
(kUA/L)

<0.35
0.35–1.9
>1.9

–7
+1
+3

Total IgE
(IU/mL)

<417
417–1000
1000–2300
>2300

-3
+1
+2
+3

Absolute eosinophil count (cells/µL)

<500
500–1000
>1000

+0
+3
+4

A. fumigatus-specific IgG
(mgA/L)

<27
>27

+0
+4

Radiological scoring
(Thorax high resolution computed tomography)

Normal

+0

≥2 features of fibrosis

+2

Bronchiectasis involving <3 lobes

+3

Bronchiectasis involving ≥3 lobes

+4

Extensive mucoid impaction

+4

Hyperattenuating mucus

+5

Total score

ABPA risk

Radiological score 0, Total 8

ABPA-S (serological ABPA)

Radiological score 0, Total ≥9

ABPA-CPF (ABPA with chronic pleuropulmonary fibrosis)

Radiological score 2, Total ≥9

ABPA-B (ABPA with bronchiectasis)

Radiological score 3 or 4, Total ≥9

ABPA-HAM (ABPA with high attenuated mucus)

Radiological score 5, Total ≥9
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remission. Clinical worsening was accepted as an
increase in cough, sputum and respiratory distress.
Stage 4 (Remission), continuous clinical-radiological
improvement and total IgE level below baseline (or less
than 50% increase) 6 months after treatment.
Stage 5.
Stage 5a (Treatment-dependent), ≥2 exacerbation
within 6 months after stopping treatment or worsening
of the clinical and/or radiological condition, along with
immunological worsening (rise in IgE levels) on tapering
oral steroids/azoles.
Stage 5b (Corticosteroid-dependent asthma), Systemic
glucocorticoids required for control of asthma while the
ABPA activity is controlled (as indicated by IgE levels and
thoracic imaging).
Stage 6 (Advance), Extensive bronchiectasis due to
ABPA on chest imaging and complications (cor pulmonale
and/or chronic type II respiratory failure).
We evaluated thorax high resolution computed
tomography (HRCT) findings for both diagnosis and
radiological staging. We recorded the values FVC (forced
vital capacity), FEV1 (forced expiratory volume in 1 s)
and FEV1/FVC with spirometry. During the follow-up of
the patients’ clinical, laboratory, imaging and spirometric
findings, treatment regimens, treatment responses, and
side effects were recorded.
Categorical data were expressed as numbers,
percentages (%), continuous data as mean ± standard
deviation, or median (minimum-maximum). Statistical
analyses of the study were performed using IBM SPSS
Statistics for Windows, v. 25. This study was approved
by Dokuz Eylül University Non-Interventional Research
Ethics Committee (2020/21-28, 14.09.2020).
3. Results
The mean age of the 6 patients was 14.66 ± 1.52 years.
Three of these patients were diagnosed with asthma, and
the other three were diagnosed with cystic fibrosis. The
average age of diagnosis in cystic fibrosis patients was 4.33
± 1.52 months, while in asthma patients it was 10.66 ±
5.50 years. The median follow-up month of the patients
after ABPA diagnosis was 7 (min-max: 4–12) months. The
demographic findings of the patients are summarized in
Table 2.
At the time of ABPA diagnosis; the median total IgE
level was 1033 IU/mL (1004–6129), the median absolute
eosinophil count (AEC) was 566/µL (200–800). Only in
our third case, AEC was lower than 500/µL, however, our
patient had high values in the past. Median AF specific
IgE mean of the patients was 10.64 kU/L (2.59–49.70).
IgG specific to A. fumigatus could not be observed in any
of our patients. The total score could be calculated in all
of our patients except for the 4th patient since it was ≥ 9
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independent of the AF specific IgG parameter. The total
scores of our other patients were between 10 and 12, and
were consistent with the diagnosis of ABPA-B. Diagnostic
scores and laboratory findings calculated when patients
were diagnosed with ABPA are summarized in Table 3.
The skin prick tests of our patients are summarized in
Table 4.
Except for one case (case 4), bronchiectasis was
detected in HRCT of 5 other cases. Mosaic perfusion areas,
peribronchial thickening, cystic lesions, budding tree sign,
nonspecific nodule, pulmonary infiltration were other
remarkable radiological findings. HRCT findings of our
patients are shown in Figure 1.
In spirometry, the rate of FVC, FEV1 and FEV1/FVC
was found to be low in our 3rd and 6th patients while it
was over 80% in our other patients (Table 2). We detected
an increase of approximately 20% in FEV1 levels after the
first month of ABPA treatments in our 3rd and 6th cases,
and this improvement continued throughout their clinical
follow-ups. In our second case, spirometric evaluation
could not be performed due to the poor general condition.
We preferred a high dose of ICS and oral itraconazole
treatment in patients with asthma with ABPA. Treatment
regimens vary in our cystic fibrosis patients. Treatment
protocols and doses of patients are shown in Table 5.
Our third case used oral methylprednisolone for about
5 months with ABPA diagnosis approximately 2 years ago,
6 months after the cessation of itraconazole treatment,
and the same treatment protocol used for the second time
for 9 months with the diagnosis of relapse ABPA. Due to
the development of an ABPA attack for the third time 3
months after the treatment, we started the treatment of
oral methylprednisolone and posaconazole. However,
although we saw the desired total IgE decrease in the first
month of treatment, we planned a treatment change due
to the development of steroid-related enterocolitis. For
this reason, we started the subcutaneous omalizumab
treatment. Spirometric values increased to >80% after the
first month of treatment, and significant improvement in
clinical findings was observed from the 2nd week.
Total IgE levels of our cases were recorded at the time
of diagnosis and during their follow-up. We learned that
our fourth case voluntarily stopped treatment in the 2nd
month of treatment and later had asthma attacks. We
followed up again by ensuring patient compliance. Since
our second case died, it could not be followed up. Figure 2
shows the changes in total IgE levels during the follow-up
of the cases.
4. Discussion
ABPA is defined by various clinical and immunological
responses to Aspergillus fumigatus antigens [9]. Long-term
azithromycin therapy; bacterial bronchial colonization;

Compound heterozygous
p.G542X, p.N1303K

3m
Homozygous
p.Phe508 del
-

Predisposing condition diagnosis age
(month/year)

Genetic disorder

Bacterial colonization

Presence of atopy in the patient
(nonfungal)
95
104
91
+
+

FEV₁

FVC

FEV₁/FVC

The presence of atopy in the family

Relationship between parents

Spirometry (initial)

6m

Cystic fibrosis

Predisposing condition

-

-

-

-

+

Pseudomonas aeruginosa

Cystic fibrosis

F

F

Sex
Female/Male

16

13

Case 2

Age (year)

Case 1

Table 2. Demographic findings of the patients.

+

-

65

67

44

+

Staphylococcus aureus

Compound heterozygous
p.Phe508del p.N130K

4m

Cystic fibrosis

M

15

Case 3

M

17

Case 5

-

+

102

78

80

+

-

-

7y

-

-

91

108

102

+

-

Heterozygous
p.I556V

17y

Allergic asthmaAllergic asthma
SAFS

F

12

Case 4

-

+

78

85

67

+

-

-

8y

Allergic asthma
-SAFS

F

13

Case 6
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Table 3. Diagnostic scores and laboratory findings of patients at admission.
Case 1

Case 2

Case 3

Case 4

Case 5

Case 6

8
3
11
ABPA-B*

8
4
12
ABPA-B*

6
4
10
ABPA-B*

0
-

8
4
12
ABPA-B*

8
4
12
ABPA-B*

Total IgE (IU/mL)

1004

1944

6129

1036

1004

1031

AEC† (/uL)

600

500

200

800

600

700

AF Specific IgE‡ (kU/L)

19.20

49.70

7.09

1.99

14.20

2.59

Immunological score
Radiological score
Total score
Scoring result

*: Allergic bronchopulmonary aspergillosis with bronchiectasis, †: Absolute eosinophil count, ‡: Aspergillus fumigatus
Table 4. Skin prick yest (SPT) results of patients
SPT (mm)

Case 1

Case 2

Case 3

Case 4

Case 5

Case 6

Positive control

3

4

3

3

3

4

Weed/Grain pollen

-

7

7

8

4

4

Olive pollen

-

8

-

8

-

-

Alder pollen

-

-

-

-

4

-

Cat dander

-

-

-

5

-

-

A. alternata*

-

-

-

8

4

7

C.herbarum†

-

-

-

4

-

3

A. fumigatus‡

5

7

4

4

5

4

*: Alternaria alternata, ‡: Aspergillus fumigatus, †: Cladosporium herbarum

use of high-dose inhaled corticosteroids; genetic factors
such as CFTR gene mutations and the presence of atopy
and eosinophilia have been reported to increase the risk
of ABPA [10]. Similar risk factors were present in our
patients, as seen in Table 2. Our fourth and sixth cases
were diagnosed with SAFS. Two of our 3 patients who
developed ABPA with CF had eosinophilia. We think that
the presence of atopy and eosinophilia in cystic fibrosis
patients may be risk factors for ABPA and care should
be taken in terms of the development of ABPA in these
patients. Three of our patients who developed ABPA with
asthma had fungal sensitivity and two were being followed
up for severe asthma. Because of the possibility that
patients with similar characteristics may be at increased
risk of developing ABPA and clinical progression may be
faster than in other asthma groups, close monitoring may
be needed in the follow-up of these patients.
The criteria defined in adults are used for the diagnosis
of ABPA in children. However, the cut-off value of total
IgE for ABPA is not well defined in children. In the study
conducted in children between the ages of 5–15, total
IgE 1204 IU/L and AF specific IgE 0.49 KUA/L were

2558

recommended for the diagnosis of ABPA [11]. In another
study with an average age of 35.9, it was reported that the
sensitivity of A. fumigatus specific IgE >1.91 kUA/L, total
IgE >2347 IU/mL and total eosinophil count >507 cells/
µL cut-off values were 70% and specificity was 100% in
asthma patients [12]. Our patients’ total IgE levels were
in the range of 1004–6129 IU/L and Aspergillus specific
IgE levels were in the range of 1.99–49.7 kU/L. We found
the highest total IgE and aspergillus specific IgE levels in
our patients with CF. However, in order not to delay the
diagnosis of ABPA or to prevent unnecessary long-term
drug use, we think that extensive studies are needed to
clarify the cut-off values according to the young age groups
and predisposing disease.
For the diagnosis of ABPA disease, a scoring system
including radiological and immunological scores was
proposed [6]. The scoring result of our 5 patients was
consistent with ABPA-B diagnosis. Due to the lack of
sharp cut-off values, this scoring system can be applied
more easily in paediatric patients compared to current
diagnostic criteria, but care must be taken in the differential
diagnosis.

ATAY et al. / Turk J Med Sci

Figure 1. High-resolution computed tomography images of the patients. 1a. Peribonchial thickening, 1b. Cystic areas, 1c. Budding tree
sign, 1d. Nonspecific nodule, 1e. Pulmonary infiltration, 1f. Central bronchiectasis.
Table 5. Treatment protocols of patients.
Treatment protocol
Case 1

High-dose inhaled fluticasone propionate* and oral itraconazole‡

Case 2

Oral methyl prednisolone† and oral itraconazole‡

Case 3

Oral methyl prednisolone† and posaconazole§ → omalizumab||

Case 4

High-dose inhaled fluticasone propionate/salmeterol¶ and montelukast and oral itraconazole‡

Case 5

High-dose inhaled fluticasone propionate* and oral itraconazole‡

Case 6

High-dose inhaled fluticasone propionate/salmeterol¶ and montelukast and oral itraconazole‡

*: Fluticasone propionate 1 mg/day.
‡: Oral itraconazole 5 mg/kg (max: 400 mg/day)- about 16 weeks/up to 1 month after steroid cut.
†: Oral methyl prednisolone. Beginning with 2 mg/kg/day, reducing the dose every 2 weeks, going over everyday and
cutting after 3 months.
§: Posaconazole. First day 2 x 300 mg, then 1 x 300 mg, 6–12 weeks
||: Omalizumab 300 mg subcutan every 2 weeks.
¶: Inhaled fluticasone propionate/salmeterol 250/50 mcg-2x2.

The most obvious radiological findings in ABPA are
bronchiectasis and pulmonary infiltration. Glove finger
appearance caused by secretion-filled bronchi, train rail
appearance, lobar collapse and local consolidation, are
other radiological findings. HRCT has been the preferred
radiological imaging method in ABPA because of its high
sensitivity in the diagnosis of bronchiectasis and showing

other abnormalities well [6]. We detected bronchiectasis in
5 of HRCT images taken at the time of diagnosis. Paediatric
patients are afraid of tomography shots because of their
potential risks. As an alternative to this diagnostic imaging
method, we thought it might be useful to evaluate the position
of ultrasonic imaging methods in diagnosis and follow-up in
terms of findings that cannot be detected by AC radiography.
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65

67
70
101
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1.day
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Omalizumab
1.month
94
86
89

omalizumab
5.month
85
92
108

Figure 2. Spirometric changes in the follow-up of our third case.

Spirometry helps to show obstruction in airflow,
however, normal spirometry does not exclude asthma
or ABPA diagnosis [13]. However, it is a useful tool for
monitoring lung functions during follow-up [14]. Except
for our third case, where spirometric measurements
of our patients were not very low despite their clinical
picture. The FEV1 and FEV1/FVC values of our third
case were significantly increased with one month of oral
methylprednisolone and posaconazole treatment, but no
change was detected in FVC. At the 24th hour of the first
dose of omalizumab treatment, FVC improved markedly
and it was observed that all parameters exceeded 80% in
the 1st month (Figure 3).
Agarwal et al. proposed a clinical staging in patients
with ABPA. At the time of diagnosis, only our third patient
was compatible with Stage 5a (treatment-dependent) and
the others were in Stage 1 (Acute). Identification and close
follow-up of patients in the asymptomatic stage will be
important to prevent the progression of the disease [6].
It has also been reported in studies that a cut-off value
of 1000 IU/mL can help differentiate SAFS from ABPA-S.
It was emphasized that these patients can be labeled as
‘ABPA- at risk’ and close monitoring and follow-up should
be performed [15]. In our 4 and 6 cases in the SAFS clinic,
we found that the symptom control was insufficient despite
the 5th step treatment. We concluded that the addition of
itraconazole therapy would be beneficial in preventing
chronic lung findings in patients ABPA with asthma who
have not received the desired clinical response despite the
increase of step therapy. Extensive research is still needed
to investigate the relationship between SAFS and ABPA.
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There are treatment recommendations according to
stages in ABPA. Oral glucocorticosteroids recommended
in Stage 1 cases may be reduced and discontinued in
Stage 2 while the patient is in remission. Itraconazole
is recommended to be added to treatment in patients
with relapse (stage 3) or in patients with corticosteroiddependent asthma (stage 4). It is not clear whether
any treatment is effective in patients who develop endstage pulmonary fibrosis [16,17]. However, systemic
corticosteroids and antifungals have often failed due
to inadequate symptom control and undesirable side
effects; consequently, alternative treatments have been
investigated [18]. Long-term oral steroid therapy is
particularly problematic for CF patients who are already
prone to diabetes, osteopenia and growth retardation
[19]. Omalizumab is used in patients with severe allergic
asthma, with a steroid-protective effect. Based on these
results, it has been suggested that omalizumab may be
beneficial in patients with ABPA [20]. While high dose
ICS and oral itraconazole treatment was preferred in our
patients with asthma with ABPA, treatment regimens
were different in patients with CF. We preferred the
combination of OCS and itraconazole in our patient with
a poor clinical condition and the combination of ICS and
itraconazole in our patient with aeroallergen sensitivity.
Oral corticosteroids (OCS) and posaconazole treatment
was discontinued in our patient who came with relapse and
then omalizumab treatment was started. The place of ICS
in ABPA treatment was evaluated in a review. While ICS
treatment was effectively detected in several case reports
and small case series, it was reported to be of no benefit in

ATAY et al. / Turk J Med Sci
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Figure 3. Changes in total IgE levels of cases.

a double-blind multicenter placebo-controlled study [6].
In addition to being an antifungal, itraconazole increases the
systemic bioavailability of inhaled corticosteroids. Therefore,
it has been assumed that this effect of itraconazole causes a
clinical response but increases the potential side effects of the
steroid [21,22]. We preferred ICS and itraconazole treatment
in four of our patients and we did not encounter any side
effects. In our patient using OCS, enterocolitis developed and
we thought that the patient who had growth retardation due to
CF may have additional problems due to steroid use. We have

experienced in our patient that ICS, itraconazole treatment is
beneficial in patients with aeroallergen sensitivity and caught
at an early stage. Therefore, we think it would be beneficial
to re-evaluate this combination in large patient populations.
The effects of omalizumab treatment on spirometry
have led to contradictory results in studies. In some studies,
FEV1 (forced expiratory volume in 1 s) and FVC (forced
vital capacity) values did not improve, while some case
reports showed improvement [23]. In our third case, we
observed a significant improvement in FEV1 and FVC
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when we compared the onset and 24th hour of Omalizumab
treatment. And this improvement continues with subsequent
doses of omalizumab.
During ABPA treatment, control of chest radiography
and serum total IgE levels are recommended every 6–8
weeks [6]. We evaluated the clinical findings, total IgE
levels and chest radiographs after 1 month of treatment.
Our fourth patient had a 16% decline in the total IgE level,
while the others were 25% and above. Treatment change
was not considered in our fourth patient due to the good
clinical condition and radiological findings. However,
we associated more than 50% increase in 3rd-month
control with the patient’s treatment mismatch. With the
reorganization of the treatment, we detected a 23% decrease
in the 1st month. While our third case saw a dramatic
decrease in the total IgE level up to the 4th month, we
observed that the 6th month increased more than twice the
last level. We did not plan a treatment change considering
that total IgE level was affected by omalizumab treatment
and the presence of atopy due to no clinical or radiological
deterioration. Even though there was a 33% increase in the
total IgE level in the 4th month of the treatment of our sixth
case, we thought that this situation was related to seasonal
weed pollen sensitivity due to the absence of complaints
and clinical findings. Especially in patients with allergen
sensitivity and using Omalizumab therapy, it is necessary
to decide that the total IgE level is misleading, considering
the other findings of the patient. We think that it would be
beneficial to bring a different parameter to be used in the
follow-up of these patients.

In conclusion; even though immunopathogenesis,
genetic, and environmental risk factors for ABPA have
been investigated, they have not yet been revealed clearly.
ABPA diagnostic criteria and treatment regimens have
not yet been customized for paediatric patients. For this
reason, considering the underlying predisposing disease in
paediatric patients, cutt-off values, diagnostic criteria and
scoring systems for total IgE, AF-specific IgE, AEC should
be determined. Thus, by developing treatment regimens
suitable for clinical stages, patients can be protected from
drug side effects.
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